IRICoR, UdeM, IRIC and Valence Discovery collaborate to design novel drug candidates
IRICoR, Université de Montréal, IRIC and Valence Discovery collaborate to design novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson’s disease patients
A leading researcher at Université de Montréal will leverage IRICoR’s expertise in accelerating drug discovery projects and Valence’s AI-enabled platform to design highly selective drug candidates against a newly identified target.
MONTREAL and CAMBRIDGE, Mass., March 10, 2021 […]